Loading…
Generate Biomedicines, Inc.
Generate Biomedicines, Inc. (GENB) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Somerville, United States and has 312 employees. The company is worth $1.55B. Revenue was $31.89M in fiscal 2025, up 55.9% from the year before. It reported a net loss of $203.15M. The share price is 46.7% below its 52-week high of $22.67. 3 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Renaissance Technologies, at $669.49K. In that quarter, 1 of them reduced the position. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| NTLAIntellia Therapeutics, Inc. | $11.16 | — | 2.1x | 0.00% | -55.44% | $1.56B |
| GPCRStructure Therapeutics Inc. | $21.93 | — | 1.2x | 0.00% | -20.21% | $1.56B |
| CERTCertara, Inc. | $10.09 | — | 1.6x | 0.00% | -2.21% | $1.54B |
| RAREUltragenyx Pharmaceutical Inc. | $15.95 |
| — |
| — |
| 0.00% |
| — |
| $1.57B |
| MAZEMaze Therapeutics, Inc. | $27.53 | — | 3.4x | 0.00% | -37.35% | $1.53B |
| AZTAAzenta, Inc. | $36.01 | — | 1.0x | 0.00% | -7.04% | $1.58B |